Parasitological and Pathological Observations on <i>Schistosoma bovis</i> Sonsion, 1876, in Calves, Sheep and Goats in Iran

Massoud, J.

doi:10.1017/s0022149x00023853

Cited by 23 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1983a). Others working on S. bouis and the closely-related S. mattheei have also reported suppression of worm fecundity as an important manifestation of acquired immunity in experimental infections (Massoud 1973, Massoud & Nelson 1972, Lawrence 1973, 1977 and the possibility that this phenomenon is also of importance in human schistosomiasis must be considered . Certainly, experimentally-infected rhesus monkeys show suppression of worm fecundity in S .…”

Section: Discussionmentioning

confidence: 99%

Suppression of Schistosoma bovis egg production in cattle by vaccination with either glutathione S‐transferase or keyhole limpet haemocyanin

Bushara

Bashir

Malik

et al. 1993

Parasite Immunology

View full text Add to dashboard Cite

Two of the antigens which have shown vaccine potential in animal experiments against Schistosoma mansoni are glutathione-S-transferase (GST) and GP38, protective epitopes of which are shared with keyhole limpet haemocyanin (KLH). We therefore tested S. bovis GST and KLH for vaccine efficacy against S. bovis in the natural Zebu cattle host. In a preliminary experiment three vaccinations with a total of 1.39 mg of native GSTs of S. bovis induced specific antibody at the time of challenge as detected by Western blotting and ELISA and mean faecal egg counts between weeks 6-10 post-challenge were reduced by 56.4 to 82.5% compared to non-vaccinated controls. Mean adult worm recoveries and tissue egg densities in large intestine and liver samples were also reduced in the vaccinated group, but these differences were not statistically significant. In a subsequent experiment one group of calves was vaccinated with a similar schedule to that used above; a second group of calves was given only two injections of GST (total 0.48 mg protein); a third group of calves was vaccinated twice with a total of 2.0 mg KLH in PBS. All three vaccination schedules induced specific antibody. Both GST vaccination schedules induced significant reductions in faecal egg counts compared to non-vaccinated controls and in this experiment tissue egg densities were also significantly reduced. A striking finding, however, was that adult worm counts were not reduced by vaccination. An essentially similar outcome resulted from KLH vaccination, since there were significant reductions in faecal and tissue egg counts in the absence of a reduction in adult worm numbers.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Section: Discussionmentioning

confidence: 99%

Suppression of Schistosoma bovis egg production in cattle by vaccination with either glutathione S‐transferase or keyhole limpet haemocyanin

Bushara

Bashir

Malik

et al. 1993

Parasite Immunology

View full text Add to dashboard Cite

show abstract

“…Interestingly, GSTs have been prominently identified from the vesicles in this study and other proteomic analyses of schistosome EVs [20,27,28]. This manifestation of protective immunity is seen in cattle which have had repeated field and laboratory exposure to S. bovis [93,94] and the closely-related S. matheei [95], in Rhesus monkeys experimentally infected with S. mansoni [96], and in baboons following laboratory exposure to S. haematobium [97]. In the cattle/ S. bovis and baboon/ S. haematobium models, this observation was confirmed by surgically transplanting “suppressed” worms into hosts with no prior exposure and showing that the parasites resumed high levels of egg production [91,97].…”

Section: Discussionmentioning

confidence: 64%

Schistosoma haematobiumextracellular vesicle proteins confer protection in a heterologous model of schistosomiasis

Mekonnen

Tedla

Pickering

et al. 2020

Preprint

View full text Add to dashboard Cite

29Helminth parasites release extracellular vesicles which interact with the surrounding host 30 tissues, mediating host-parasite communication and other fundamental processes of 31 parasitism. As such, vesicle proteins present attractive targets for the development of 32 novel intervention strategies to control these parasites and the diseases they cause. Herein, 33 we describe the first proteomic analysis by LC-MS/MS of two types of extracellular 34 vesicles (exosome-like, 120k pellet vesicles and microvesicle-like, 15k pellet vesicles) 35 from adult Schistosoma haematobium worms. A total of 57 and 330 proteins were 36 identified in the 120k pellet vesicles and larger 15k pellet vesicles, respectively, and some 37 of the most abundant molecules included homologues of known helminth vaccine and 38 diagnostic candidates such as Sm-TSP2, Sm23, glutathione S-tranferase, saposins and 39 aminopeptidases. Tetraspanins were highly represented in the analysis and found in both 40 vesicle types. Vaccination of mice with recombinant versions of three of these 41 tetraspanins induced protection in a heterologous challenge (S. mansoni) model of 42 infection, resulting in significant reductions (averaged across two independent trials) in 43 liver (47%, 38% and 41%) and intestinal (47%, 45% and 41%) egg burdens. These 44 findings offer insight into the mechanisms by which anti-tetraspanin antibodies confer 45 protection and highlight the potential that extracellular vesicle surface proteins offer as 46 anti-helminth vaccines.47 48 Introduction 52Schistosomiasis is the second most important parasitic disease, only after malaria, 53 in terms of social, economic and public health impact [1]. Schistosoma haematobium, the 54 causative agent of urogenital schistosomiasis, is highly prevalent in 53 Middle East and 55 African countries [1] and it is also sporadically seen in India [2] and France [3]. Urogenital 56 schistosomiasis affects more than 90 million people, mostly in sub-Saharan Africa where 57 180 million inhabitants are at risk, and is responsible for 150,000 deaths per year [4]. 58Furthermore, the most common complications associated with this disease include 59 schistosomal haematuria, bladder wall pathology, hydronephrosis, and dysuria [4]. 60The current control programs against schistosomiasis are aimed at reducing the 61 morbidity caused by the parasite by regularly treating infected populations with 62 praziquantel [5]. Despite the efforts made to control this devastating disease, 63 schistosomiasis is still spreading to new geographical areas [3,6]. Furthermore, 64 praziquantel has shown reduced efficacy in field studies [7] and is not effective against 65 the immature stages of the parasite [8,9]. Hence, a vaccine that reduces disease severity 66 and/or reduces transmission is needed to control and eliminate schistosomiasis [10,11]. 67Despite efforts over decades, there is no licensed vaccine [1,12]. Even though various 68 vaccine candidates have advanced into clinical trials targeting Schistosoma mansoni, ...

show abstract

“…Interestingly, GSTs have been prominently identified from the vesicles in this study and other proteomic analyses of schistosome EVs [ 20 , 27 , 28 ]. This manifestation of protective immunity is seen in cattle that have had repeated field and laboratory exposure to S. bovis [ 93 , 94 ] and the closely-related S. matheei [ 95 ], in Rhesus monkeys experimentally infected with S. mansoni [ 96 ], and in baboons following laboratory exposure to S. haematobium [ 97 ]. In the cattle/ S. bovis and baboon/ S. haematobium models, this observation was confirmed by surgically transplanting “suppressed” worms into hosts with no prior exposure and showing that the parasites resumed high levels of egg production [ 91 , 97 ].…”

Section: Discussionmentioning

confidence: 99%

Schistosoma haematobium Extracellular Vesicle Proteins Confer Protection in a Heterologous Model of Schistosomiasis

et al. 2020

View full text Add to dashboard Cite

Helminth parasites release extracellular vesicles which interact with the surrounding host tissues, mediating host–parasite communication and other fundamental processes of parasitism. As such, vesicle proteins present attractive targets for the development of novel intervention strategies to control these parasites and the diseases they cause. Herein, we describe the first proteomic analysis by LC-MS/MS of two types of extracellular vesicles (exosome-like, 120 k pellet vesicles and microvesicle-like, 15 k pellet vesicles) from adult Schistosoma haematobium worms. A total of 57 and 330 proteins were identified in the 120 k pellet vesicles and larger 15 k pellet vesicles, respectively, and some of the most abundant molecules included homologues of known helminth vaccine and diagnostic candidates such as Sm-TSP2, Sm23, glutathione S-transferase, saponins and aminopeptidases. Tetraspanins were highly represented in the analysis and found in both vesicle types. Vaccination of mice with recombinant versions of three of these tetraspanins induced protection in a heterologous challenge (S. mansoni) model of infection, resulting in significant reductions (averaged across two independent trials) in liver (47%, 38% and 41%) and intestinal (47%, 45% and 41%) egg burdens. These findings offer insight into the mechanisms by which anti-tetraspanin antibodies confer protection and highlight the potential that extracellular vesicle surface proteins offer as anti-helminth vaccines.

show abstract

Parasitological and Pathological Observations on Schistosoma bovis Sonsion, 1876, in Calves, Sheep and Goats in Iran

Cited by 23 publications

References 10 publications

Suppression of Schistosoma bovis egg production in cattle by vaccination with either glutathione S‐transferase or keyhole limpet haemocyanin

Suppression of Schistosoma bovis egg production in cattle by vaccination with either glutathione S‐transferase or keyhole limpet haemocyanin

Schistosoma haematobiumextracellular vesicle proteins confer protection in a heterologous model of schistosomiasis

Schistosoma haematobium Extracellular Vesicle Proteins Confer Protection in a Heterologous Model of Schistosomiasis

Contact Info

Product

Resources

About